First City Capital Management, Inc. Incyte Corp Transaction History

First City Capital Management, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 13, 2021	SELL	$76.02 - $100.5 $223,042 - $294,867	-2,934 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$80.74 - $97.7 $31,004 - $37,516	-384 Reduced 11.57%	2,934 $249,000
Q3 2020 Nov 16, 2020	BUY	$85.07 - $109.69 $75,201 - $96,965	884 Added 36.32%	3,318 $0
Q2 2020 Aug 14, 2020	BUY	$74.18 - $108.93 $180,554 - $265,135	2,434 New	2,434 $253,000
Q1 2020 May 15, 2020	SELL	$63.18 - $85.97 $153,780 - $209,250	-2,434 Closed	0 $0
Q4 2019 Feb 10, 2020	BUY	$73.04 - $95.72 $177,779 - $232,982	2,434 New	2,434 $213,000
Q3 2019 Nov 13, 2019	SELL	$72.82 - $86.52 $230,038 - $273,316	-3,159 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$73.52 - $88.7 $1,838 - $2,217	-25 Reduced 0.79%	3,159 $268,000
Q1 2019 May 13, 2019	SELL	$63.56 - $88.17 $63,560 - $88,170	-1,000 Reduced 23.9%	3,184 $274,000
Q4 2018 Feb 13, 2019	SELL	$58.5 - $69.94 $32,175 - $38,467	-550 Reduced 11.62%	4,184 $266,000
Q2 2018 Aug 13, 2018	BUY	$60.85 - $83.98 $15,760 - $21,750	259 Added 5.79%	4,734 $317,000
Q1 2018 May 15, 2018	BUY	$83.06 - $100.98 $371,693 - $451,885	4,475 New	4,475 $373,000

644

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of First City Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on First City Capital Management, Inc. with notifications on news.